DFW, Great Point Partners, SK Capital and Water Street Healthcare Partners are among the PE firms investing in pharma ...

Following the FDA’s approval Monday of its muscular dystrophy drug, Cambridge, Mass.-based Sarepta Therapeutics plans to sell up to $255 million of stock and use the proceeds to fund clinical trials, ...

Insilico Medicine and Qilu Pharmaceutical Group announced a strategic collaboration to jointly develop small-molecule inhibitors for cardiometabolic diseases, combining Insilico’s generative AI–driven ...

Health tech company Waltz Health will merge with Eversana with the goal of shaking up access to prescription drugs. The deal will bring together Waltz's proprietary drug marketplaces and ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced a discovery ...

Every year, university researchers discover potential new drugs, diagnostics, and medical devices that could transform patient care. Yet many of those ideas stall in the "valley of death," the stretch ...

Combined company offers next-generation commercialization model that directly connects life sciences to payers and patients to accelerate access, improve affordability and transform drug value across ...

Rounding up five deals in the pharma commercialization segment, and delving into trends driving that activity; a discussion ...

Amarin Corporation Plc (NASDAQ:AMRN) on Tuesday entered into an exclusive long-term license and supply agreement with Recordati S.p.A., Italy, to commercialize Vazkepa (icosapent ethyl) in 59 ...

Last month, the US Food and Drug Administration (FDA) approved two new drugs and two biosimilars as well as halted commercialization for a hemophilia treatment. Here’s a deeper look of what happened ...